RecruitingNCT06838143

Ilaris NIS in Korea

Studying Hereditary periodic fever syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals
Novartis Pharmaceuticals
Intervention: Ilaris(biological)
Enrollment: 25 enrolled
Eligibility: 2-100 years · All sexes
Timeline: 2025 – 2028

Study locations (1)

Novartis Investigative Site, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06838143 on ClinicalTrials.gov

Other trials for Hereditary periodic fever syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001373
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
National Human Genome Research Institute (NHGRI)

See all trials for Hereditary periodic fever syndrome →

← Back to all trials